<DOC>
	<DOCNO>NCT01207804</DOCNO>
	<brief_summary>The purpose study provide initial clinical data support feasibility use ValenTx Endo Bypass system enhance weight loss co-morbidity resolution morbidly obese patient .</brief_summary>
	<brief_title>Feasibility Trial ValenTx Endo Bypass System</brief_title>
	<detailed_description>This single center open label feasibility study evaluate safety , efficacy performance ValenTx Endo Bypass system .</detailed_description>
	<criteria>Male female 18 55 year age &gt; =35 kg/m2 &lt; = 50 kg/m2 , without comorbid condition ( ) . Documented failure nonsurgical weight loss method Willing comply study procedure visit schedule Willing able provide Informed Consent Pregnancy intention become pregnant within study duration . Endoscopic lesion important hiatal hernia , gastric duodenal ulcer , atresias stenosis , polyps stomach . Subject potential upper gastrointestinal bleeding esophageal gastric varix , MalloryWeis syndrome congenital acquire intestinal telangiectasia . Past history esophageal gastric/GI surgery , obstruction , adhesive peritonitis , large hiatal hernia ( &gt; 3 cm ) . IBS , unexplained intermittent vomiting , severe abdominal pain chronic constipation within 60 day study day 1 Unexplained anaemia , Pancreatitis , Portal hypertension , Esophagitis Barrett 's esophagus , know gallstone anomaly GI tract Any bodily infection within 30 day study day 1 . Prolonged steroid use Hep C HIV positive Known allergy device material Use weight loss medication investigational drug device within 2 month prior enrolment throughout study period . Recent ongoing cancer , history severe renal , hepatic , cardiovascular pulmonary disease transplant Inability tolerate antiinflammatory medication Evidence psychiatric problem dietary habit would contraindicate study treatment ; Active drug alcohol addiction within 12 month enrolment throughout study duration . Prior history inflammatory diseases GI tract , ( e.g. , esophagitis , varix , gastric duodenal ulceration , Crohn 's disease ; congenital acquire GI anomaly , e.g. , bowel stricture ) Ongoing treatment anticoagulant , steroid , aspirin , NSAIDs , gastric irritant within 1 month prior enrollment throughout study period . Participation previous ( within 60 day study day 1 ) ongoing clinical trial current past usage ( within 60 day study day 1 ) investigation drug device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Obesity</keyword>
</DOC>